Last quarter (Q2 2022), Sinopharm Group Co's total revenue was ¥―, a decrease of ― from the same quarter last year. In Q2, Sinopharm Group Co's net income was ¥―. See Sinopharm Group Co’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	¥ 521.05B	¥ 456.41B	¥ 425.02B	¥ 344.30B	¥ 307.67B
Cost of Revenue	-	¥ 477.00B	¥ 416.09B	¥ 387.74B	¥ 313.30B	¥ 282.30B
Gross Profit	-	¥ 44.05B	¥ 40.32B	¥ 37.28B	¥ 31.01B	¥ 25.36B
Operating Expense	-	¥ 22.61B	¥ 20.54B	¥ 19.03B	¥ 15.47B	¥ 12.81B
Operating Income	-	¥ 21.44B	¥ 19.78B	¥ 18.50B	¥ 15.53B	¥ 12.55B
Net Non Operating Interest Income Expense	-	¥ -3.40B	¥ -2.94B	¥ -3.14B	¥ -2.77B	¥ -2.08B
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	¥ 17.00B	¥ 15.60B	¥ 13.76B	¥ 12.21B	¥ 11.23B
Tax Provision	-	¥ 3.94B	¥ 3.50B	¥ 3.14B	¥ 2.80B	¥ 2.56B
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	¥ 7.76B	¥ 7.19B	¥ 6.25B	¥ 5.83B	¥ 5.57B
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	¥ 499.61B	¥ 436.63B	¥ 406.77B	¥ 328.77B	¥ 295.11B
Net Income From Continuing And Discontinued Operation	-	¥ 7.76B	¥ 7.19B	¥ 6.25B	¥ 5.84B	¥ 5.58B
Normalized Income	-	¥ 9.44B	¥ 8.96B	¥ 8.17B	¥ 7.07B	¥ 5.37B
Interest Expense	-	¥ 3.76B	¥ 3.42B	¥ 3.44B	¥ 3.07B	¥ 2.80B
EBIT	-	¥ 20.76B	¥ 19.02B	¥ 17.20B	¥ 15.28B	¥ 14.02B
EBITDA	-	¥ 24.68B	¥ 22.62B	¥ 17.20B	¥ 16.67B	¥ 15.27B

Currency in CNY

Sinopharm Group Co Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing